ARVN Arvinas Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ARVN

Price (delayed)

$87.33

Market cap

$4.3B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.67

Enterprise value

$4.25B

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing ...

Highlights
The company's equity has surged by 195% YoY but it fell by 5% QoQ
The quick ratio has surged by 101% year-on-year but it has declined by 10% since the previous quarter
The company's net income has shrunk by 91% YoY and by 18% QoQ
The EPS has plunged by 57% YoY and by 12% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://arvinas.com
Peers: OTIC ORIC

Key stats

What are the main financial stats of ARVN
Market
Shares outstanding
49.2M
Market cap
$4.3B
Enterprise value
$4.25B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.34
Price to sales (P/S)
204.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
203.3
Earnings
Revenue
$20.9M
EBIT
-$163.56M
EBITDA
-$158.26M
Free cash flow
-$142.5M
Per share
EPS
-$3.67
Free cash flow per share
-$2.92
Book value per share
$11.9
Revenue per share
$0.43
TBVPS
$13.18
Balance sheet
Total assets
$644.03M
Total liabilities
$61.08M
Debt
$5.62M
Equity
$582.95M
Working capital
$585.91M
Liquidity
Debt to equity
0.01
Current ratio
15.01
Quick ratio
14.65
Net debt/EBITDA
0.3
Margins
EBITDA margin
-757.3%
Gross margin
100%
Net margin
-782.9%
Operating margin
-806.2%
Efficiency
Return on assets
-28.3%
Return on equity
-32%
Return on invested capital
-60.1%
Return on capital employed
-27.2%
Return on sales
-782.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARVN stock price

How has the Arvinas stock price performed over time
Intraday
-1.44%
1 week
-5.37%
1 month
2.24%
1 year
257.62%
YTD
2.83%
QTD
13.42%

Financial performance

How have Arvinas's revenue and profit performed over time
Revenue
$20.9M
Gross profit
$20.9M
Operating income
-$168.49M
Net income
-$163.62M
Gross margin
100%
Net margin
-782.9%
ARVN's operating income has plunged by 151% YoY and by 18% from the previous quarter
The company's net income has shrunk by 91% YoY and by 18% QoQ
Arvinas's revenue has plunged by 55% YoY
The gross profit has plunged by 55% YoY

Growth

What is Arvinas's growth rate over time

Valuation

What is Arvinas stock price valuation
P/E
N/A
P/B
7.34
P/S
204.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
203.3
The EPS has plunged by 57% YoY and by 12% from the previous quarter
The company's equity has surged by 195% YoY but it fell by 5% QoQ
The stock's price to book (P/B) is 38% more than its last 4 quarters average of 5.4
The P/S is 58% above the last 4 quarters average of 131.0
Arvinas's revenue has plunged by 55% YoY

Efficiency

How efficient is Arvinas business performance
The company's return on invested capital has shrunk by 52% YoY but it rose by 19% QoQ
ARVN's return on equity is up by 28% year-on-year and by 4.2% since the previous quarter
The ROS has contracted by 19% from the previous quarter
ARVN's return on assets is up by 13% year-on-year

Dividends

What is ARVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARVN.

Financial health

How did Arvinas financials performed over time
ARVN's total assets has soared by 145% YoY but it is down by 6% from the previous quarter
ARVN's current ratio has soared by 103% YoY but it is down by 9% QoQ
The debt is 99% smaller than the equity
The company's equity has surged by 195% YoY but it fell by 5% QoQ
The debt to equity has plunged by 50% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.